DIRECTED BIOTICS
Dead / Abandoned — Abandoned — failure to respond (as of 20 Oct 2020)
What this means for you
This application is over — abandoned 09 Oct 2020. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88755639
- Mark type
- Stylized text
- Filed
- 11 Jan 2020
- Abandoned
- 09 Oct 2020
- Attorney of record
- David S. Kerr
Goods and services
- Class 042 — Scientific and technological services: Medical research and development in the field of synthetic biology, molecular biology, genetic engineering and bioinformatics; Design and development of biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals for use in pharmaceuticals, biotechnology, and medical and diagnostic applications; Research and development of biopharmaceutical compounds; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit mosquito populations; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target genes; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit mosquito populations; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce eukaryotic-like mRNA; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce commercial compounds; Research and development services, namely, RNA-based systems for yield management in plants; ; Research and development services, namely, plant transformation, plant transformation, bacterial-mediated transient eukaryotic cell transformation; Bioinformatic services, namely, rational design of novel pharmaceuticals, therapeutics and biologics
Owner
- PEBBLE LABS USA INC., SANTA FE, NM, US
Prosecution history
- 20 Oct 2020 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 20 Oct 2020 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 08 Apr 2020 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 08 Apr 2020 — NON-FINAL ACTION E-MAILED
- 08 Apr 2020 — NON-FINAL ACTION WRITTEN
- 30 Mar 2020 — ASSIGNED TO EXAMINER
- 16 Jan 2020 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 15 Jan 2020 — NEW APPLICATION ENTERED